# Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

> **NCT04722575** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fondazione Melanoma Onlus** · enrollment: 95 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Cobimetinib 20 MG Oral Tablet
- **DRUG:** Vemurafenib 240 Mg Oral Capsule
- **DRUG:** Atezolizumab 1200 MG in 20 ML Injection

## Key facts

- **NCT ID:** NCT04722575
- **Lead sponsor:** Fondazione Melanoma Onlus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-12
- **Primary completion:** 2023-12-15
- **Final completion:** 2027-06
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2025-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04722575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04722575, "Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04722575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*